| Field | Specification |
|---|---|
| Target | |
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C25H30N6O5 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
BAY1082439 is an orally bioavailable, selective inhibitor of PI3Kα/β/δ that also inhibits mutated forms of PIK3CA. It is highly effective at inhibiting the growth of Pten-null prostate cancer[1][2]. It is supplied as a white to off-white solid (C25H30N6O5, MW 494.54) at 99.35% purity.
Physical & Chemical Properties
| CAS Number | 1375469-38-7 |
|---|---|
| Molecular Formula | C25H30N6O5 |
| Molecular Weight | 494.54 g/mol |
| Purity | 99.35% |
| Appearance | Solid |
| Color | White to off-white |
| SMILES | O=C(C1=CC=CN=C1C)NC2=NC3=C(C=CC(OC[C@H](O)CN4CCOCC4)=C3OC)C5=NCCN25 |
| Target | PI3Kα, PI3Kβ, PI3Kδ |
| Signaling Pathway | PI3K/Akt/mTOR; Apoptosis |
| Solubility | In Vitro: 0.1 M HCl: 16.67 mg/mL (33.71 mM; Requires sonication and warming and heat to 60°C) DMSO: 5 mg/mL (10.11 mM; Requires sonication and adjust pH to 5 with HCl; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 6 months; -20°C, 1 month. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
[1]. Ningshu Liu, et al. Abstract 2799: BAY 1082439, a highly selective and balanced PI3Kα/β inhibitor demonstrated potent activity in tumors with activated PI3Kα and loss-of-function of PTEN. Abstract nr 2799. doi:1538-7445.AM2012-2799.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| 0.1 M HCl | 16.67 mg/mL (33.71 mM) | requires sonication and warming and heat to 60°C |
| DMSO | 5 mg/mL (10.11 mM) | requires sonication and adjust pH to 5 with HCl; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration. Percentages are volume ratios of the final working solution. Prepare the working solution fresh on the day of dosing; if precipitation or phase separation occurs, gentle warming or sonication can help.
Direct preparation of the working solution
These formulations are prepared directly, without a DMSO stock; use them promptly after preparation.
Protocol 1
| Composition | 50% PEG300 + 50% saline |
|---|---|
| Result | 25 mg/mL (50.55 mM); suspension; requires sonication |
Data provided by the manufacturer.
In Vitro
BAY1082439 is a PI3Kα/α-balanced inhibitor with high selectivity. In biochemical assays, BAY1082439 gives an IC50 ratio of 1:3 for PI3Kα (4.9 nM) versus PI3Kα (15.0 nM), with >1000-fold selectivity over mTOR kinase[1]. At 0.1-1 μM for 72 hours, BAY1082439 blocks PTEN-null prostate cancer cells more effectively than PI3Kα- and/or PI3Kβ-selective inhibitors[2].
Cell Viability Assay[2]
| Cell Line | PC3 and LNCaP cells (PTEN-null human prostate cancer cell lines) |
|---|---|
| Concentration | 0.1, 0.33, 1, 3.3, 10 μM |
| Incubation Time | 72 hours |
| Result | Efectively inhibited cell growth by blocking the G1/S cell cycle transition and by inducing apoptosis. |
In Vivo
Given at 75 mg/kg (p.o.) daily for 4 weeks, BAY1082439 effectively prevents progression of Pten-null prostate cancer[2].
| Animal Model | Pten conditional knockout mouse model (Pb-Cre+;PtenL/L, CP model)[2] |
|---|---|
| Dosage | 75 mg/kg |
| Administration | P.o.; daily for 4 weeks |
| Result | Significantly decreased tumor size and P-AKT staining, nearly normal luminal architecture, and a significant reduction of Ki67-positive cells. Significantly inhibit the human prostate cancer growth. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
SSRN. 2026 May 20.
